Loading...
Docoh

Applied Dna Sciences (APDN)

Applied DNA is commercializing LinearDNA™, its proprietary, large-scale polymerase chain reaction ('PCR')-based manufacturing platform that allows for the large-scale production of specific DNA sequences. The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market. The platform is used to manufacture DNA for customers as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive cell therapies (CAR T and TCR therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, and gene therapies. Applied DNA has also established a COVID-19 diagnostic and testing offering that is in the early stages of commercialization and is grounded in the Company's deep expertise in DNA. The LinearDNA platform also has non-biologic applications, such as supply chain security, anti-counterfeiting and anti-theft technology. Key end-markets include textiles, pharmaceuticals and nutraceuticals, and cannabis, among others.

Company profile

Ticker
APDN
Exchange
Website
CEO
James Hayward
Employees
Incorporated
Location
Fiscal year end
Former names
DATALINK CAPITAL CORP/TX/, DCC ACQUISITION CORP, PROHEALTH MEDICAL TECHNOLOGIES INC
SEC CIK
Subsidiaries
APDN (B.V.I.) Inc. • Applied DNA Sciences Europe Limited • Applied DNA Sciences India Private Limited • LineaRX, Inc. • Applied DNA Clinical Labs LLC ...
IRS number
592262718

APDN stock data

Analyst ratings and price targets

Last 3 months

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

12 May 22
26 Jun 22
30 Sep 22
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Sep 21 Sep 20 Sep 19 Sep 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 6.51M 6.51M 6.51M 6.51M 6.51M 6.51M
Cash burn (monthly) (no burn) 617.77K 664.78K 1.22M 87.3K 827.14K
Cash used (since last report) n/a 1.77M 1.91M 3.51M 250.81K 2.38M
Cash remaining n/a 4.74M 4.6M 3M 6.26M 4.14M
Runway (months of cash) n/a 7.7 6.9 2.5 71.7 5.0

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Nov 21 Jantzen Beth NQSO Common Stock Grant Acquire A No No 5.58 25,205 140.64K 25,205
1 Nov 21 Jantzen Beth Incentive Stock Option Common Stock Grant Acquire A No No 5.58 19,924 111.18K 19,924
1 Nov 21 Shamash Yacov A NQSO Common Stock Grant Acquire A No No 5.58 11,937 66.61K 11,937
1 Nov 21 Shamash Yacov A Incentive Stock Option Common Stock Grant Acquire A No No 5.58 19,897 111.03K 19,897
1 Nov 21 Simon Sanford R NQSO Common Stock Grant Acquire A No No 5.58 10,197 56.9K 10,197
1 Nov 21 Simon Sanford R Incentive Stock Option Common Stock Grant Acquire A No No 5.58 19,897 111.03K 19,897
1 Nov 21 Anchin Scott L NQSO Common Stock Grant Acquire A No No 5.58 9,948 55.51K 9,948
1 Nov 21 Anchin Scott L Incentive Stock Option Common Stock Grant Acquire A No No 5.58 19,897 111.03K 19,897
1 Nov 21 Catell Robert B NQSO Common Stock Grant Acquire A No No 5.58 9,948 55.51K 9,948
1 Nov 21 Catell Robert B Incentive Stock Option Common Stock Grant Acquire A No No 5.58 19,897 111.03K 19,897
13.9% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 22 24 -8.3%
Opened positions 5 7 -28.6%
Closed positions 7 3 +133.3%
Increased positions 4 8 -50.0%
Reduced positions 7 5 +40.0%
13F shares Current Prev Q Change
Total value 2.19M 2.4M -8.9%
Total shares 1.04M 616.6K +68.9%
Total puts 0 64.5K EXIT
Total calls 16.4K 113K -85.5%
Total put/call ratio 0.6
Largest owners Shares Value Change
Armistice Capital 459.77K $984K NEW
Vanguard 213.75K $458K -21.4%
BLK Blackrock 83.02K $177K +7.7%
Dimensional Fund Advisors 65.92K $141K +53.0%
Geode Capital Management 53.37K $114K 0.0%
Atria Wealth Solutions 31.26K $67K NEW
STT State Street 26.98K $58K +53.6%
Delta Investment Management 25K $54K -44.4%
VIRT Virtu Financial 22.97K $49K NEW
CVI Investments 18.38K $0 0.0%
Largest transactions Shares Bought/sold Change
Armistice Capital 459.77K +459.77K NEW
Vanguard 213.75K -58.32K -21.4%
Citadel Advisors 0 -43.81K EXIT
Atria Wealth Solutions 31.26K +31.26K NEW
VIRT Virtu Financial 22.97K +22.97K NEW
Dimensional Fund Advisors 65.92K +22.84K +53.0%
Delta Investment Management 25K -20K -44.4%
Creative Planning 10.67K +10.67K NEW
STT State Street 26.98K +9.42K +53.6%
Simplex Trading 76 -6.59K -98.9%

Financial report summary

?

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: accrual, Bulletin, calendar, Carlo, categorized, charged, concurrent, conflict, corroborated, Distinguishing, Egypt, exclusive, frequency, fundamental, geopolitical, half, hierarchy, identical, immaterial, inception, independent, instability, invaded, investor, listed, military, minimal, Monte, overarching, paying, political, promulgated, quoted, reliance, Russia, SAB, shelf, simulation, thereunder, transition, treatment, Ukraine, umbrella, unobservable, unrealized, voluntary, week, west, wider, withdrawal
Removed: America, announced, certified, complexity, concentrate, declaration, detect, Dillon, exist, forward, Hill, impacted, infected, informing, justifying, letter, pattern, protect, referred, return, review, revocation, secured, sensitivity, shown, specifically, utility

Patents

Utility
Method of marking cellulosic products
4 Jan 22
Methods for marking cellulosic products, including cellulosic fibers such as lyocell and cellulosic films, including methods for marking such products with a detectable nucleic acid marker to identify and validate the origin or authenticity of the products or items manufactured using such products.
Utility
Compositions and Methods for Detecting and Treating SARS-COV-2
23 Sep 21
The present invention relates generally to PCR-based in vitro diagnostics and methods of treatment for SARS-CoV-2, the virus that causes COVID-19, and more specifically, to compositions and methods for the detection of wildtype and variants of SARS-CoV-2 in a patient specimen and methods of treating SARS-CoV-2 based on said detection.
Utility
Amplicon Expression Vector Vaccines
19 Aug 21
Provided herein are non-plasmid derived DNA vaccines comprised solely of enzymatically produced amplicon expression vectors and their method of use to elicit antigen-specific immune responses in a subject.
Utility
System and Method for Manufacturing Error Mitigated Polynucleotides
15 Jul 21
The present invention relates generally to molecular biology, and more specifically, to a system and method for the manufacture of quantities of error mitigated polynucleotides via the polymerase chain reaction (PCR).
Utility
Nucleic Acid Coated Micron and Submicron Particles for Authentication
3 Jun 21
A composition comprising micron or submicron particles covered by a monolayer of nucleic acid wherein the nucleic acid may be recovered from the submicron particles is claimed.